NASDAQ: VERAVera Therapeutics Inc Stock
$25.22+1.12 (+4.65%)
Updated Nov 6, 2025
VERA Price
$25.22
Fair Value Price
$0.69
Market Cap
$1.61B
52 Week Low
$18.53
52 Week High
$51.61
P/E
-6.32x
P/B
4.04x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$251.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.3
Operating Cash Flow
-$210M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VERA Overview
Vera Therapeutics, Incorporated develops treatments for patients with serious immunological diseases in the U.S. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. Known as Trucode Gene Repair, Inc. until 2020, Vera Therapeutics was incorporated in 2016 and is headquartered in Brisbane, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VERA's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VERA
Ranked#452 of 481
Ranked#452 of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.33 | A | |
| $105.20 | A | |
| $134.05 | A |
Be the first to know about important VERA news, forecast changes, insider trades & much more!
VERA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VERA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VERA ($25.22) is overvalued by 3,571.19% relative to our estimate of its Fair Value price of $0.69 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VERA ($25.22) is not significantly undervalued (3,571.19%) relative to our estimate of its Fair Value price of $0.69 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VERA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VERA due diligence checks available for Premium users.
Valuation
VERA fair value
Fair Value of VERA stock based on Discounted Cash Flow (DCF)
Price
$25.22
Fair Value
$0.69
Overvalued by
3,571.19%
VERA ($25.22) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VERA ($25.22) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VERA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VERA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.32x
Industry
252.41x
Market
45.67x
VERA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.04x
Industry
4.85x
VERA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VERA's financial health
Profit margin
Revenue
$0.0
Net Income
-$80.3M
Profit Margin
0%
VERA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$517.5M
Liabilities
$118.6M
Debt to equity
0.3
VERA's short-term assets ($511.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VERA's short-term assets ($511.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VERA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$61.9M
Investing
$69.8M
Financing
$797.0k
VERA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VERA vs Biotech Stocks
Vera Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.